Real-time Estimate
Other stock markets
|
5-day change | 1st Jan Change | ||
37.54 USD | +0.43% | +13.20% | +73.70% |
May. 15 | Spyre Therapeutics, Inc. Announces Board Changes | CI |
May. 13 | Wells Fargo Adjusts Price Target on Spyre Therapeutics to $40 From $35, Maintains Overweight Rating | MT |
This article is reserved for members
Already a member?
Log InNot a member ?
Free registrationEPS Revisions
1st Jan change | Capi. | |
---|---|---|
+73.70% | 1.51B | |
+7.52% | 113B | |
+11.38% | 106B | |
+1.08% | 22.27B | |
-12.64% | 22.22B | |
-5.57% | 19.43B | |
-37.85% | 17.87B | |
-8.58% | 17.24B | |
+7.77% | 14.29B | |
+37.41% | 12.52B |
- Stock Market
- Equities
- SYRE Stock
- News Spyre Therapeutics, Inc.
- Aeglea BioTherapeutics Names Jeffrey Goldberg Chief Executive Officer